-
Company Profile
Flatiron Health Inc – Company Profile
Flatiron Health Inc. (Flatiron Health), a subsidiary of F. Hoffmann-La Roche Ltd, is a health tech company that focuses on improving cancer treatment and advancing research. The company's main activities include providing technology and services to support patient care, partnering with cancer centers and collaborating with global developers of oncology therapeutics. Flatiron offers a range of products and services, including Flatiron Clinical Pipe, OncoTrials, Flatiron Vessel and a suite of real-world evidence solutions. Flatiron's products and services are used by...
Add to Basket -
Company Insights
Pfizer Inc – Digital Transformation Strategies
Pfizer Inc Digital Transformation Strategies Overview Pfizer uses AI and data analytics to accelerate drug discovery and enhance operational efficiencies as a part of its digital transformation strategies. The annual ICT spending of Pfizer was estimated at $3.6 billion in 2022. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Pfizer Inc (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and...
-
Company Insights
Flatiron Health – Tech Innovator Profile
Flatiron Health (Flatiron), a subsidiary of Roche Holding AG, is a healthcare technology company that is involved in accelerating cancer research.
-
Analyst Opinions
Healthcare Industry Business Confidence Report H1 2018
GlobalData’s "Healthcare Industry Business Confidence Report H1 2018", examines executives’ opinion about the business environment during H1 2018. It also highlights current economic conditions, supplier price variations, sales performance, industry and company growth prospects, spending models, and key priorities. Additionally, the report provides information categorized by region. The existing economic climate is stable for the healthcare industry, and customer confidence levels will remain positive during H1 2018 (April 2018-September 2018). The majority of executives who operate in Asia-Pacific and North...